Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:38:53 2024-07-16 pm EDT			5-day change	1st Jan Change
0.46 ^USD	-0.33%		-6.01%	-56.60%

May. 28	Ensysce Biosciences Back in Compliance With Nasdaq	MT
May. 20	Sector Update: Health Care Stocks Softer Late Afternoon	MT

Ensysce Biosciences, Inc. Appoints Dr. Linda Pestano as Chief Development Officer

October 26, 2021 at 08:00 am EDT

Ensysce Biosciences, Inc. has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021. Dr. Pestano joins Ensysce with 20 years of experience developing vaccines, drugs and novel biologics for a diverse range of indications.

Latest news about Ensysce Biosciences, Inc.

Ensysce Biosciences Back in Compliance With Nasdaq	May. 28	MT
Sector Update: Health Care Stocks Softer Late Afternoon	May. 20	MT
Sector Update: Health Care	May. 20	MT
Ensysce Biosciences Renews Collaboration with Quotient Sciences for Pain Killer Drug Study	May. 20	MT
Ensysce Biosciences, Inc. Announces Renewal of Collaboration with Quotient Sciences to Undertake the Study PF614-MPAR-102 to Examine and Evaluate the Full Commercial Dose Range of the PF614-MPAR Drug Product	May. 20	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Ensysce Biosciences Announces Successful Meeting with Fda for Pf614-Mpar, A Next Generation Opioid with Overdose Protection	Feb. 21	CI
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript	Feb. 15	CI
Ensysce Shares Rally After FDA Feedback on Pain Medication	Jan. 31	DJ
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain	Jan. 31	CI
Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR	Jan. 23	DJ
Wall Street Set to Open Flat as Investors Eye Key Manufacturing Index	Jan. 23	MT
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic	Dec. 14	CI
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States	Nov. 28	CI
Ensysce Biosciences, Inc. announced that it has received $1.7 million in funding	Nov. 27	CI
Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study	Nov. 16	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Ensysce Biosciences, Inc. announced that it expects to receive $1.7 million in funding	23-10-22	CI
Top Premarket Gainers	23-10-09	MT
Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study	23-09-26	CI
HC Wainwright Adjusts Ensysce Biosciences Price Target to $7 From $9, Maintains Buy Rating	23-09-25	MT
Transcript : Ensysce Biosciences, Inc. - Special Call	23-09-21
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies	23-09-14	CI

Chart Ensysce Biosciences, Inc.

Duration

Period

More charts

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ensysce Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENSYSCE BIOSCIENCES, INC.	-56.60%	3.5M
MODERNA, INC.	+25.53%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.24%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.19%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.85%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.97%	14.52B
MEDPACE HOLDINGS, INC.	+47.52%	13.74B
BIO-TECHNE CORPORATION	+3.18%	12.17B

Other Biotechnology & Medical Research